Biosimilars in the U.S. Market: Knowns and Unknowns

  • November 22, 2016
  • 1:00 PM – 2:00 PM ET
  • Online

Even with the approval of four biosimilars in the U.S., there are still uncertainties and questions that remain unanswered.

This webinar will educate stakeholders on some key topics related to the evolution of the U.S. biosimilar landscape and marketplace.

Webinar participants will learn:

  • Differences in biologic and biosimilar regulatory approval pathways
  • Uncertainties in naming and labeling of biosimilars and their potential implications
  • Knowns and unknowns related to coverage, coding, and payment of biosimilars across various stakeholders
  • Potential impact of unknowns on market access for biosimilars

Who should attend:

  • Payers
  • Formulary decision-makers
  • Health care community


Kathleen E. Hughes, Vice President, Avalere Health
Kathy Hughes advises Avalere clients on value strategies, market access, and evidence planning. Kathy partners with life sciences companies to scrutinize complex issues in market access, craft strategies and tactics to address them, and plan for and perform the analytics necessary for their success.

Prior to joining Avalere, Kathy was co-leader of the Market Access practice at Covance and the Chief Operating Officer at Holy Cross Health Corp. She has also served as Vice President for Corporate and Strategic Planning for Blue Shield of California and Senior Manager with Ernst & Young’s Healthcare Management consulting practice.

Kathy has a BA from Brandeis University and a MBA from the University of Chicago. She also has a Certificate of Completion from the Mid-Atlantic Health Leadership Institute at the Johns Hopkins Bloomberg School of Public Health and is a Senior Fellow at the Thomas Jefferson University School of Population Health.